Inotiv, Inc. (NOTV) Analyse boursière

Présentation de l'entreprise

Inotiv, Inc. (NOTV) delivers nonclinical and analytical services for drug discovery and development within the pharmaceutical and medical device sectors, operating across the United States, the Netherlands, and international markets. The enterprise functions through two primary segments, Discovery and Safety Assessment (DSA) and Research Model, positioning it within the Healthcare sector specifically under the Diagnostics & Research industry. This specialized industry focus implies a reliance on scientific data generation and regulatory compliance for clients seeking to advance therapeutic candidates before human trials. The company operates with a market capitalization of $9.18M and generates annual revenue of $514.03M, supported by an employee base of 1945 individuals. The disparity between the relatively small market cap and the substantial revenue figure suggests that the company is trading at a significant discount relative to its earnings power, reflecting investor caution regarding its profitability or capital structure rather than a lack of operational scale.

Santé financière

Inotiv reported a Trailing Twelve Months (TTM) revenue of $514.03M, yet it recorded a net income loss of $69,373,000 and an EBITDA of $17.68M, indicating a substantial gap between top-line generation and bottom-line profitability. This wide divergence between revenue and net income reveals a cost structure where operating expenses or other non-operating charges significantly erode the earnings generated from sales. The company generated negative free cash flow of $-3,620,125, which indicates a lack of financial flexibility to fund operations or investments without external capital infusion during this reporting period. Profitability metrics further highlight these challenges, with a gross margin of 23.5%, an operating margin of -13.4%, and a profit margin of -13.5%. The negative operating and profit margins demonstrate that for every dollar of revenue, the company loses money after covering all operating costs and taxes. Regarding liquidity and leverage, the firm holds $12.73M in cash against $475.97M in debt, resulting in a highly leveraged balance sheet characterized by a debt-to-equity ratio of 436.57. Short-term liquidity is constrained as evidenced by a current ratio of 0.30, meaning current assets are only 30% of current liabilities, posing potential risks in meeting immediate obligations. Finally, the return on equity stands at -49.8% while return on assets is -3.1%, metrics that reveal management has not yet been effective in generating returns on the capital deployed or shareholder equity due to persistent losses.

Évaluation de la valorisation

Valuation metrics for Inotiv present a complex picture, with a P/E ratio (TTM) of N/A and a forward P/E of -5.34. The absence of a trailing P/E combined with a negative forward P/E implies that the market is pricing in future earnings recovery or is valuing the company based on non-earnings multiples due to current unprofitability. The price-to-book ratio is recorded at 0.08, indicating that the stock trades at a fraction of its book value, which suggests the market does not assign a premium to the company's assets or expects significant impairment. Alternative valuation measures include a price-to-sales ratio of 0.02 and an EV/EBITDA of 26.72; the extremely low P/S ratio suggests the market values sales very cheaply, while the high EV/EBITDA multiple reflects the heavy debt load relative to earnings power. Price action over the last year shows a 52-week high of $3.32 and a 52-week low of $0.24, meaning the stock has experienced extreme volatility within this range. The beta of 4.08 indicates that the stock's price volatility is more than four times that of the broader market, making it a highly sensitive instrument to market swings and sector-specific news.

Growth & Income

Revenue growth for the company stands at 0.8% year-over-year, while earnings growth is N/A. The stagnation in revenue growth combined with the inability to report earnings growth implies that the company is struggling to expand its market share or increase pricing power to cover its high cost structure. As a non-dividend payer, Inotiv offers no dividend yield and maintains a payout ratio of 0.0%, which signifies that the company reinvests its limited cash flow into operations or debt reduction rather than returning capital to shareholders. The overall growth and income profile is defined by minimal revenue expansion and a complete absence of dividend income, reflecting a phase of financial restructuring or investment in future capabilities rather than current shareholder returns.